In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The biopharmaceutical giant AstraZeneca is considering moving their stock listing from the London Stock Exchange to the US in ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...

AstraZeneca boss Sir Pascal Soriot (pictured) is thought to be mulling shifting its listing to New York due to growing ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

(Reuters) -AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United ...

Neurofibromatosis Type 2 Market Insight, Epidemiology And Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

UK stocks bucked a trend across European equities to end the day in the green, with a late boost from AstraZeneca following a ...

In June, 2025, the UK government announced plans to boost science and technology research and development (R&D) in the country, pledging to invest £86 billion in the sector over the next 4 years. The ...